Novavax Aktie
7,22
EUR
+0,02
EUR
+0,25
%
8,54
USD
-0,01
USD
-0,06
%
nachbörslich
Novavax jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Es gab keine Analysen zu dieser Aktie in den letzten sechs Monaten.
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| AstraZeneca PLC | 5 | 3 | 0 | 138,72 GBP | - |
| Bayer | 2 | 7 | 0 | 26,88 EUR | -1,18% |
| BioNTech (ADRs) | 4 | 2 | 0 | 135,33 USD | +37,98% |
| CanSino Biologics Inc. Registered Shs -A- | 0 | 0 | 0 | - | - |
| CureVac | 0 | 1 | 0 | - | - |
| Fresenius Medical Care (FMC) St. | 3 | 4 | 3 | 47,89 EUR | +9,54% |
| Fresenius SE & Co. KGaA (St.) | 8 | 2 | 0 | 50,81 EUR | +9,58% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| Inovio Pharmaceuticals Inc | 0 | 0 | 0 | - | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Moderna Inc | 0 | 1 | 0 | 42,00 USD | +71,50% |
| Novartis AG | 3 | 4 | 2 | 98,25 CHF | -0,15% |
| Novavax Inc. | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 3 | 4 | 0 | 29,33 USD | +23,44% |
| Roche AG (Genussschein) | 3 | 2 | 3 | 280,90 CHF | +10,81% |
| Sanofi S.A. | 8 | 1 | 0 | 110,75 EUR | +41,90% |
| Sinopharm Group Co Ltd (H) | 0 | 0 | 0 | - | - |
| Valneva | 0 | 0 | 0 | - | - |